DV
Dividend Vision

EQ — Equillium, Inc.

Equillium, Inc. (EQ)

Total return is -83.1% over the past 7.8 years, 299.4 points behind SPY at 216.3%. Its deepest 1-year drawdown was 57.8%.

Equillium, Inc. is a clinical-stage biotechnology company developing therapeutics for severe autoimmune and inflammatory disorders, with lead programs including EQ504, an AhR modulator in preclinical development for ulcerative colitis and lung inflammation, and EQ302, a bi-specific inhibitor targeting celiac disease. The company does not currently have an established distribution history. This security may appeal to investors seeking exposure to early-stage biotech development with a focus on immuno-inflammatory disease treatment.

EQ key facts

Asset type
Stock
Asset class
Equity
Inception date
10/12/2018
Distribution frequency
None
Last close
$2.36
Market cap
$149,643,056
Average volume
538000.0
Beta
1.811
Payout ratio
0.0
Forward P/E
1.5314
EPS
$-0.09